AstraZeneca Asthma Drug Fasenra Receives FDA Approval
November 15 2017 - 2:53AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that its Fasenra drug
for the treatment of asthma has received approval from the U.S.
Food and Drug Administration based on the results of a phase 3
program.
The pharmaceutical company said the program showed a reduction
of up to 51% in the annual asthma exacerbation rate, significant
improvement in lung function, and allowed for a median 75%
reduction in steroid use in patients.
The FDA approved the drug for patients 12 years and older, with
severe asthma driven by eosinophilic inflammation, AstraZeneca
reported.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 15, 2017 02:38 ET (07:38 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024